U.S. FDA Approves Edurant PED (rilpivirine) for Certain Pediatric Patients Living with HIV-1 - This approval offers a new HIV-1 treatment option for children in the U.S. at least 2 years of age, weighing 14 kg – 25 kg and living with HIV

Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved EDURANT^® PED (rilpivirine) for the treatment of HIV-1 in combination with other antiretroviral therapies (ARVs) in treatment-naïve children (with HIV-1 RNA <100,000 copies/mL) at least 2 years of age and weighing at least 14 kg and less than 25 kg. This approval builds on Johnson & Johnson’s longstanding commitment to ensuring that people living with HIV, including children, have treatment options that may work for them.

Additional information to the following link: https://www.janssen.com/us-fda-approves-edurant-ped-rilpivirine-certain-pediatric-patients-living-hiv-1